PVLA Relative Valuation
PVLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PVLA is overvalued; if below, it's undervalued.
Historical Valuation
Palvella Therapeutics Inc (PVLA) is now in the Fair zone, suggesting that its current forward PS ratio of 53466.81 is considered Fairly compared with the five-year average of -13.02. The fair price of Palvella Therapeutics Inc (PVLA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：97.38
Fair
-25.63
PE
1Y
3Y
5Y
-24.36
EV/EBITDA
Palvella Therapeutics Inc. (PVLA) has a current EV/EBITDA of -24.36. The 5-year average EV/EBITDA is -10.23. The thresholds are as follows: Strongly Undervalued below -25.14, Undervalued between -25.14 and -17.69, Fairly Valued between -2.77 and -17.69, Overvalued between -2.77 and 4.69, and Strongly Overvalued above 4.69. The current Forward EV/EBITDA of -24.36 falls within the Undervalued range.
-23.40
EV/EBIT
Palvella Therapeutics Inc. (PVLA) has a current EV/EBIT of -23.40. The 5-year average EV/EBIT is -11.15. The thresholds are as follows: Strongly Undervalued below -22.97, Undervalued between -22.97 and -17.06, Fairly Valued between -5.24 and -17.06, Overvalued between -5.24 and 0.67, and Strongly Overvalued above 0.67. The current Forward EV/EBIT of -23.40 falls within the Strongly Undervalued range.
53466.81
PS
Palvella Therapeutics Inc. (PVLA) has a current PS of 53466.81. The 5-year average PS is 11851.16. The thresholds are as follows: Strongly Undervalued below -27594.83, Undervalued between -27594.83 and -7871.83, Fairly Valued between 31574.16 and -7871.83, Overvalued between 31574.16 and 51297.15, and Strongly Overvalued above 51297.15. The current Forward PS of 53466.81 falls within the Strongly Overvalued range.
-33.09
P/OCF
Palvella Therapeutics Inc. (PVLA) has a current P/OCF of -33.09. The 5-year average P/OCF is -14.92. The thresholds are as follows: Strongly Undervalued below -35.55, Undervalued between -35.55 and -25.23, Fairly Valued between -4.60 and -25.23, Overvalued between -4.60 and 5.71, and Strongly Overvalued above 5.71. The current Forward P/OCF of -33.09 falls within the Undervalued range.
-29.41
P/FCF
Palvella Therapeutics Inc. (PVLA) has a current P/FCF of -29.41. The 5-year average P/FCF is -14.04. The thresholds are as follows: Strongly Undervalued below -29.56, Undervalued between -29.56 and -21.80, Fairly Valued between -6.28 and -21.80, Overvalued between -6.28 and 1.48, and Strongly Overvalued above 1.48. The current Forward P/FCF of -29.41 falls within the Undervalued range.
Palvella Therapeutics Inc (PVLA) has a current Price-to-Book (P/B) ratio of 28.75. Compared to its 3-year average P/B ratio of 10.56 , the current P/B ratio is approximately 172.15% higher. Relative to its 5-year average P/B ratio of 10.56, the current P/B ratio is about 172.15% higher. Palvella Therapeutics Inc (PVLA) has a Forward Free Cash Flow (FCF) yield of approximately -2.15%. Compared to its 3-year average FCF yield of -4.06%, the current FCF yield is approximately -47.15% lower. Relative to its 5-year average FCF yield of -4.06% , the current FCF yield is about -47.15% lower.
28.75
P/B
Median3y
10.56
Median5y
10.56
-2.15
FCF Yield
Median3y
-4.06
Median5y
-4.06
Competitors Valuation Multiple
The average P/S ratio for PVLA's competitors is 9273.99, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA) exhibits a P/S ratio of 53466.81, which is 476.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PVLA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PVLA in the past 1 year is driven by Unknown.
People Also Watch
AAPL
Apple Inc
259.04USD
-0.50%
ORCL
Oracle Corp
189.65USD
-1.65%
MSFT
Microsoft Corp
478.11USD
-1.11%
NVDA
NVIDIA Corp
185.04USD
-2.15%
META
Meta Platforms Inc
646.06USD
-0.41%
WMT
Walmart Inc
113.07USD
0.31%
AMZN
Amazon.com Inc
246.26USD
1.95%
XOM
Exxon Mobil Corp
122.91USD
3.73%
TSLA
Tesla Inc
435.8USD
1.02%
AVGO
Broadcom Inc
332.48USD
-3.21%
Frequently Asked Questions
Is Palvella Therapeutics Inc (PVLA) currently overvalued or undervalued?
Palvella Therapeutics Inc (PVLA) is now in the Fair zone, suggesting that its current forward PS ratio of 53466.81 is considered Fairly compared with the five-year average of -13.02. The fair price of Palvella Therapeutics Inc (PVLA) is between to according to relative valuation methord.
What is Palvella Therapeutics Inc (PVLA) fair value?
PVLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Palvella Therapeutics Inc (PVLA) is between to according to relative valuation methord.
How does PVLA's valuation metrics compare to the industry average?
The average P/S ratio for PVLA's competitors is 9273.99, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA) exhibits a P/S ratio of 53466.81, which is 476.52% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Palvella Therapeutics Inc (PVLA) as of Jan 08 2026?
As of Jan 08 2026, Palvella Therapeutics Inc (PVLA) has a P/B ratio of 28.75. This indicates that the market values PVLA at 28.75 times its book value.
What is the current FCF Yield for Palvella Therapeutics Inc (PVLA) as of Jan 08 2026?
As of Jan 08 2026, Palvella Therapeutics Inc (PVLA) has a FCF Yield of -2.15%. This means that for every dollar of Palvella Therapeutics Inc’s market capitalization, the company generates -2.15 cents in free cash flow.
What is the current Forward P/E ratio for Palvella Therapeutics Inc (PVLA) as of Jan 08 2026?
As of Jan 08 2026, Palvella Therapeutics Inc (PVLA) has a Forward P/E ratio of -25.63. This means the market is willing to pay $-25.63 for every dollar of Palvella Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Palvella Therapeutics Inc (PVLA) as of Jan 08 2026?
As of Jan 08 2026, Palvella Therapeutics Inc (PVLA) has a Forward P/S ratio of 53466.81. This means the market is valuing PVLA at $53466.81 for every dollar of expected revenue over the next 12 months.